HK1154052A1 - Kits for diagnosing prostate conditions - Google Patents

Kits for diagnosing prostate conditions

Info

Publication number
HK1154052A1
HK1154052A1 HK11108262.1A HK11108262A HK1154052A1 HK 1154052 A1 HK1154052 A1 HK 1154052A1 HK 11108262 A HK11108262 A HK 11108262A HK 1154052 A1 HK1154052 A1 HK 1154052A1
Authority
HK
Hong Kong
Prior art keywords
kits
diagnosing prostate
prostate conditions
conditions
diagnosing
Prior art date
Application number
HK11108262.1A
Other languages
English (en)
Inventor
Carlton D Donald
Original Assignee
Musc Found For Res Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Musc Found For Res Dev filed Critical Musc Found For Res Dev
Publication of HK1154052A1 publication Critical patent/HK1154052A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK11108262.1A 2007-01-16 2011-08-08 Kits for diagnosing prostate conditions HK1154052A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88514207P 2007-01-16 2007-01-16
PCT/US2008/051168 WO2008089236A2 (en) 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions

Publications (1)

Publication Number Publication Date
HK1154052A1 true HK1154052A1 (en) 2012-04-13

Family

ID=39636676

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11108262.1A HK1154052A1 (en) 2007-01-16 2011-08-08 Kits for diagnosing prostate conditions

Country Status (16)

Country Link
US (3) US8088603B2 (ko)
EP (1) EP2104744B1 (ko)
JP (1) JP5653042B2 (ko)
KR (1) KR101565080B1 (ko)
CN (1) CN101970685B (ko)
AP (1) AP2009004851A0 (ko)
AU (1) AU2008206258B2 (ko)
BR (1) BRPI0806779A2 (ko)
CA (1) CA2667364A1 (ko)
ES (1) ES2390083T3 (ko)
HK (1) HK1154052A1 (ko)
IL (1) IL198677A (ko)
MX (1) MX2009007564A (ko)
NZ (2) NZ596471A (ko)
WO (1) WO2008089236A2 (ko)
ZA (1) ZA200902814B (ko)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
US20100029504A1 (en) * 2007-01-16 2010-02-04 Phigenix, Inc. Detecting pax2 for the diagnosis of breast cancer
US8461126B2 (en) 2005-10-14 2013-06-11 Phigenix, Inc. Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions
US20120071347A1 (en) * 2005-10-14 2012-03-22 Phigenix, Inc. Compositions and methods for monitoring and detecting cancerous conditions
CA2772036A1 (en) * 2009-08-24 2011-03-03 Phigenix, Inc. Targeting pax2 for the treatment of breast cancer
US9255931B2 (en) 2010-06-24 2016-02-09 Morehouse School Of Medicine Method and compositions for the treatment and detection of endothelin-1 related kidney diseases
MX2014006662A (es) * 2011-12-05 2015-04-16 Phigenix Inc Direccionamiento de en2, pax2, y/o defb1 para tratamiento de afecciones de la próstata.
AU2013274036B2 (en) * 2012-06-14 2017-08-17 Dana-Farber Cancer Institute, Inc. Genome-wide method of assessing interactions between chemical entities and their target molecules
SI2946206T1 (sl) 2013-01-20 2019-06-28 Dyax Corp. Ocenjevanje, testi in zdravljenje motenj, pri katerih posreduje PKA
WO2015161189A1 (en) * 2014-04-17 2015-10-22 Cornell University Neat1 as a prognostic marker and therapeutic target for prostate cancer
WO2016172160A1 (en) * 2015-04-21 2016-10-27 Genentech, Inc. Compositions and methods for prostate cancer analysis
US10816549B2 (en) * 2015-12-15 2020-10-27 Case Western Reserve University Epithelial cancer evaluation using beta defensin
WO2018085414A1 (en) * 2016-11-02 2018-05-11 President And Fellows Of Harvard College Engineered guide rna sequences for in situ detection and sequencing
CN111454916A (zh) * 2019-01-18 2020-07-28 王泽宋 甘油醛-3-磷酸脱氢酶蛋白或其免疫性片段的新应用
CN109781988A (zh) * 2019-02-28 2019-05-21 贵州省人民医院 采用her2基因扩增法检测乳腺癌循环肿瘤细胞的特异性方法
CN114402200A (zh) 2019-04-16 2022-04-26 武田药品工业株式会社 功能性c1酯酶抑制剂(fc1-inh)的定量方法
CN110907650A (zh) * 2019-11-18 2020-03-24 复旦大学附属儿科医院 应用纳米磁珠富集尿液沉渣pax2蛋白作为诊断原发性膀胱输尿管反流生物标志物的用途
EP4076652A4 (en) 2019-12-17 2024-01-03 Chinook Therapeutics, Inc. METHODS OF TREATING SHEPHERD'S DISEASE WITH ATRASENTAN
CN112646895A (zh) * 2021-01-22 2021-04-13 深圳科诺医学检验实验室 检测基因表达量的引物、探针、试剂盒、检测方法及应用
CN113658696B (zh) * 2021-07-22 2023-07-14 四川大学华西医院 一种基于患者年龄、营养指标、肿瘤分期和肿瘤标志物联合预测胃癌预后的预测系统
CN114045336B (zh) * 2021-09-28 2024-01-02 中国人民解放军空军军医大学 Cga基因作为靶点在制备用于诊断和治疗耐药实体瘤药物的应用
CN114113633B (zh) * 2021-12-27 2024-05-24 复旦大学 用于前列腺癌危险度诊断和疗效评估的分子指标、试剂盒
CN116987680A (zh) * 2022-04-25 2023-11-03 复旦大学 支链氨基酸转氨酶1的功能获得性突变体及其应用
CN117777234B (zh) * 2023-09-20 2024-09-24 烟台蓝纳成生物技术有限公司 丹磺酰胺修饰的psma靶向化合物及其制备方法和应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020145A (en) 1989-06-30 2000-02-01 Bristol-Myers Squibb Company Methods for determining the presence of carcinoma using the antigen binding region of monoclonal antibody BR96
GB2339200B (en) 1998-06-06 2001-09-12 Genostic Pharma Ltd Genostics
US6699973B1 (en) 1998-11-19 2004-03-02 Elan Corporation, Plc Antibodies to peptides that target GIT receptors and related methods
GB9903841D0 (en) 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
US6511676B1 (en) 1999-11-05 2003-01-28 Teni Boulikas Therapy for human cancers using cisplatin and other drugs or genes encapsulated into liposomes
US20030092657A1 (en) * 1999-12-22 2003-05-15 Paul Goodyer Modulation of PAX-2 for controlled apoptosis or survival of cells
CA2422314A1 (en) * 2000-09-12 2002-03-21 Transgenetics Incorporated Microarrayed organization of transcription factor target genes
AU2001291049A1 (en) * 2000-09-15 2002-03-26 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, National Institutes Of Health, Office Of Technology Transfer Defensin-antigen fusion proteins
NZ528205A (en) * 2001-03-12 2006-09-29 Monogen Inc Cell-based detection and differentiation of disease status in a cytological sample using a panel comprising a plurality of probes
WO2004041185A2 (en) * 2002-10-31 2004-05-21 University Of Rochester Hyfroxyflutamide induced pathways related to androgen receptor negative prostate cancer cells
US20060135422A1 (en) * 2003-04-17 2006-06-22 Moskowitz David W Use of angiotensin receptor blockers (ARBs) to treat diseases associated with excess ACE
US8673634B2 (en) 2003-11-13 2014-03-18 Massachusetts Eye & Ear Infirmary Method for the treatment of hearing loss
EP1853242A4 (en) * 2005-02-25 2009-11-18 Univ Michigan SMALL STAT3 INHIBITORY MOLECULES AND USES THEREOF
US20070166728A1 (en) 2005-07-22 2007-07-19 Alphagenics, Inc. Genetic profile imaging and data-sharing device and methodology for socially relevant traits
EP2392645A1 (en) * 2005-10-14 2011-12-07 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy

Also Published As

Publication number Publication date
CN101970685B (zh) 2013-08-07
US20110229492A1 (en) 2011-09-22
JP5653042B2 (ja) 2015-01-14
US8088603B2 (en) 2012-01-03
US8445444B2 (en) 2013-05-21
AP2009004851A0 (en) 2009-06-30
ZA200902814B (en) 2010-08-25
KR20090101442A (ko) 2009-09-28
CA2667364A1 (en) 2008-07-24
AU2008206258A2 (en) 2009-10-29
EP2104744B1 (en) 2012-05-16
US20120058130A1 (en) 2012-03-08
US20100029560A1 (en) 2010-02-04
AU2008206258B2 (en) 2013-06-13
ES2390083T3 (es) 2012-11-06
IL198677A0 (en) 2010-02-17
NZ596471A (en) 2013-11-29
JP2010526278A (ja) 2010-07-29
AU2008206258A1 (en) 2008-07-24
IL198677A (en) 2013-03-24
EP2104744A2 (en) 2009-09-30
WO2008089236A2 (en) 2008-07-24
EP2104744A4 (en) 2011-05-04
BRPI0806779A2 (pt) 2011-09-13
NZ578164A (en) 2011-12-22
WO2008089236A3 (en) 2010-01-07
CN101970685A (zh) 2011-02-09
MX2009007564A (es) 2009-12-08
KR101565080B1 (ko) 2015-11-03

Similar Documents

Publication Publication Date Title
HK1154052A1 (en) Kits for diagnosing prostate conditions
PL2438445T3 (pl) Sposoby diagnozowania raków gruczołu krokowego
EP2335041A4 (en) VEHICLE TEST ARRANGEMENT
EP2340555A4 (en) PROBE BLOCK ASSEMBLY
EP2162552A4 (en) BIOMARKERS FOR MELANOMES
EP1922326A4 (en) BIOMARKERS USEFUL FOR DIAGNOSING PROSTATE CANCER AND METHOD OF USE THEREOF
EP2153325A4 (en) DIAGNOSTICIZING DEFAULT ERRORS
HK1156368A1 (en) Methods for diagnosing ischemia
EP2265642A4 (en) BIOMARKERS
HK1134690A1 (zh) 子宮內膜生物標誌物
EP2367939A4 (en) METHODS FOR THE DIAGNOSIS OR TREATMENT OF PROSTATE CANCER
EP2263086A4 (en) BIOMARKERS
EP2515115A4 (en) KIT FOR DIAGNOSIS OF PROSTATE CANCER AND DIAGNOSTIC PROCEDURE
GB0618127D0 (en) Biomarker
ZA201105184B (en) Biomarker
GB0818660D0 (en) Biomarkers
GB0807214D0 (en) Biomarkers
EP2265641A4 (en) BIOMARKERS
GB0722068D0 (en) Predictive test
GB0818658D0 (en) Biomarkers
GB0809689D0 (en) Markers for prostate cancee
GB0610835D0 (en) Incubation apparatus, water testing kits
TWI339731B (en) Probe assembly
TWI349772B (en) Testing method
GB0704515D0 (en) Diagnosing psychotic disorders

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190114